COL17A1 and neoplasm: To determine whether NAT affects tumor target expression levels, MSIs of CEACAM5, TMPRSS4, COL17A1, CLDN18, and AQP5 were compared between patients who received NAT and those who did not receive NAT, as shown in Supplementary Figure S3.